Pan-CDK Inhibition Augments Cisplatin Lethality in Nasopharyngeal Carcinoma Cell Lines and Xenograft Models

Signal Transduction and Targeted Therapy - United Kingdom
doi 10.1038/s41392-018-0010-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Synthetic Lethal Interaction of CDK Inhibition and Autophagy Inhibition in Human Solid Cancer Cell Lines

Oncology Reports
MedicineCancer ResearchOncology
2017English

Inhibition of Autophagy Potentiated the Antitumor Effect of Nedaplatin in Cisplatin-Resistant Nasopharyngeal Carcinoma Cells

PLoS ONE
Multidisciplinary
2015English

Additive and Supra-Additive Cytotoxicity of Cisplatin-Taxane Combinations in Ovarian Carcinoma Cell Lines

British Journal of Cancer
Cancer ResearchOncology
1998English

Resistance to Telomerase Inhibition by Human Squamous Cell Carcinoma Cell Lines

International Journal of Oncology
Cancer ResearchOncology
2011English

Association Between Dose and Duration of Cisplatin Exposure With Cytotoxicity Effect on Nasopharyngeal Carcinoma Stem Cell

Indian Journal of Otolaryngology and Head and Neck Surgery
OtorhinolaryngologySurgery
2018English

Inhibition of Caspase-9 Activity in Cisplatin-Resistant Head and Neck Squamous Cell Carcinoma.

Journal of Otolaryngology of Japan
Otorhinolaryngology
2002English

Establishment of Lung Cancer Patient-Derived Xenograft Models and Primary Cell Lines for Lung Cancer Study

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2018English

Erratum To: Preclinical Activity of Gefitinib in Non-Keratinizing Nasopharyngeal Carcinoma Cell Lines and Biomarkers of Response

Investigational New Drugs
OncologyPharmacology
2010English

PARP1 Is Overexpressed in Nasopharyngeal Carcinoma and Its Inhibition Enhances Radiotherapy

Molecular Cancer Therapeutics
Cancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy